多中心研究中衰弱与等待名单死亡率相关且独立于腹水和肝性脑病
在美国9个中心纳入1044例无肝细胞癌的肝移植等待名单成人,用肝脏衰弱指数(LFI)评估衰弱(LFI≥4.5为衰弱)。36%有腹水、41%有肝性脑病(HE)、25%为衰弱;校正模型中仅衰弱与等待名单死亡率独立相关(sHR 1.82,95%CI 1.31-2.52),腹水和HE不再显著。
要点
- LFI≥4.5定义衰弱,25%的肝移植等待者存在衰弱。
- 有腹水者衰弱风险更高(校正OR 1.56,95%CI 1.15-2.14),有HE者更高(OR 2.45,95%CI 1.80-3.33)。
- 校正后仅衰弱与等待名单死亡率独立相关(sHR 1.82,95%CI 1.31-2.52)。
核心结论
- 衰弱是肝硬化常见并发症,在腹水或HE患者中更常见,且与等待名单死亡率独立相关。
- LFI评分可客观量化肝硬化患者与衰弱相关的死亡风险,该风险超出肝病严重程度。
研究设计与样本
- 多中心研究,在美国9个中心纳入1044例无肝细胞癌的肝移植等待名单成人,用3项简单测试计算LFI评分,LFI≥4.5判定为衰弱。
- 采用逻辑回归分析衰弱与腹水或HE的关联,采用竞争风险回归(肝移植为竞争风险)估计等待名单死亡率(死亡或退出等待名单)的亚风险比(sHR)。
主要发现
- 研究对象中36%有腹水,41%有HE,25%为衰弱。
- 有腹水者衰弱的校正OR为1.56(95%CI 1.15-2.14),有HE者OR为2.45(95%CI 1.80-3.33),均高于无这些特征者。
- 衰弱合并腹水患者等待名单期间死亡比例为29%,衰弱合并HE患者为30%,分别高于无衰弱腹水患者的17%和无衰弱HE患者的20%。
- 单变量分析中,腹水(sHR 1.52,95%CI 1.14-2.05)、HE(sHR 1.84,95%CI 1.38-2.45)和衰弱(sHR 2.38,95%CI 1.77-3.20)与等待名单死亡率相关。
- 校正模型中仅衰弱仍与等待名单死亡率显著相关(sHR 1.82,95%CI 1.31-2.52),腹水和HE不再显著。
关键数值与推荐
- LFI评分至少4.5分提示患者为衰弱。
临床怎么用
- 原文结论指出LFI评分可用于客观量化肝硬化患者与衰弱相关的死亡风险,该风险超出肝病严重程度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Frailty is associated with mortality in patients with cirrhosis. We measured frailty using 3 simple tests and calculated Liver Frailty Index (LFI) scores for patients at multiple ambulatory centers. We investigated associations between LFI scores, ascites, and hepatic encephalopathy (HE) and mortality. METHODS: Adults without hepatocellular carcinoma who were on the liver transplantation waitlist at 9 centers in the United States (N = 1044) were evaluated using the LFI; LFI scores of at least 4.5 indicated that patients were frail. We performed logistic regression analyses to assess associations between frailty and ascites or HE and competing risk regression analyses (with liver transplantation as the competing risk) to estimate sub-hazard ratios (sHRs) of waitlist mortality (death or removal from the waitlist). RESULTS: Of study subjects, 36% had ascites, 41% had HE, and 25% were frail. The odds of frailty were higher for patients with ascites (adjusted odd ratio 1.56, 95% confidence interval [CI] 1.15-2.14) or HE (odd ratio 2.45, 95% CI 1.80-3.33) than for those without these features. Larger proportions of frail patients with ascites (29%) or HE (30%) died while on the waitlist compared with patients who were not frail (17% of patients with ascites and 20% with HE). In univariable analysis, ascites (sHR 1.52, 95% CI 1.14-2.05), HE (sHR 1.84, 95% CI 1.38-2.45), and frailty (sHR 2.38, 95% CI 1.77-3.20) were associated with waitlist mortality. In adjusted models, only frailty remained significantly associated with waitlist mortality (sHR 1.82, 95% CI 1.31-2.52); ascites and HE were not. CONCLUSIONS: Frailty is a prevalent complication of cirrhosis that is observed more frequently in patients with ascites or HE and independently associated with waitlist mortality. LFI scores can be used to objectively quantify risk of death related to frailty-in excess of liver disease severity-in patients with cirrhosis.
引用
- Lai JC, Rahimi RS, Verna EC, et al. Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study. Gastroenterology. 2019. PMID: 30668935. doi:10.1053/j.gastro.2019.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。